22 January 2024 - The US health regulator on Monday asked a host of drug makers, including Gilead Sciences, Johnson & Johnson and Novartis, to add a serious warning on the label of their cancer therapies that use CAR-T technology.

The other cancer therapies include Bristol Myers Squibb's Breyanzi and its partnered therapy, Abecma, with 2seventy bio, J&J unit Janssen and Legend Biotech's Carvykti, Novartis' Kymriah, and Gilead unit Kite's Tecartus and Yescarta.

Read Reuters article